drugset
drugset / Trial / NCT05634915

Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation

NCT05634915 ↗

Phase 4 Unknown 90 enrolled The First Affiliated Hospital of Soochow University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this prospective, open-label, pairing design, single-center study is to evaluate the effect of individualized rATG dosing vs traditional weight-based rATG dosing regimen（10mg/kg）for patients with acute leukemia undergoing a myeloablative conditioning regimen and haploidentical hematopoietic stem cell transplantation (haplo-HSCT).

Timeline

Start
2022-12-20
Primary completion
2024-12-01
Completion
2025-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Thymoglobulin Protein / enzyme biologic 10 mg/kg Intravenous

Indications

acute leukemia disease related to hematopoietic stem cell transplant